Seegene a leading developer of multiplex PCR technologies, has announced that it is introducing the first three comprehensive Allplex assays using its next-generation qPCR technology, called MuDT. The assay launch menu includes a 26-target Respiratory Full Panel, a 26-target Gastrointestinal Infection Full Panel, and a 27-target Sexually Transmitted Infection Full Panel.

MuDT is a disruptive qPCR technology that allows simultaneous detection and quantification of multiple target analytes in a single fluorescence channel, without melt curve analysis after amplification. With the introduction of these new Allplex assays, Seegene now provides the most comprehensive multiplexed PCR molecular infectious disease panels in the industry.

"We have spent tremendous effort on developing innovative PCR chemistry technologies to meet the needs of molecular laboratory professions. Because MuDT enables the detection of multiple target genes in a single channel without melt curve analysis, MuDT is a true next-generation qPCR technology that will re-invigorate the real-time PCR based market. The Allplex assays can be an crucial clinical tool in accurate and cost-effective disease/symptom-based diagnosis and the efficient management of patient care," said Dr Chun, Jong-Yoon, founder, CTO and CEO of Seegene.

The company will feature its new Allplex infectious disease portfolio at the MEDICA 2014 trade fair in Düsseldorf, Germany.